

## IN BRIEF

 IMAGING**Polyps in technicolour**

Colorectal cancer (CRC) can be prevented by colonoscopy using white light to detect polyps that are then removed. However, small and flat polyps are difficult to detect using this technique. Burggraaf *et al.* have tested fluorescence-guided colonoscopy using the agent GE-137, a cyclic peptide that binds the extracellular receptor MET, which is overexpressed in early stages of CRC. Intravenous administration of GE-137 conjugated to a fluorescent dye enabled visualization of all neoplastic polyps that were visible, as well as additional polyps that were not visible, with white light in patients with CRC.

**ORIGINAL RESEARCH PAPER** Burggraaf, J. *et al.* Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. *Nat. Med.* **21**, 955–961 (2015)

 TUMOUR IMMUNOLOGY**T<sub>Reg</sub> cells, more than a suppression problem**

Chronic intestinal inflammation is associated with the development of colorectal cancer. Regulatory T (T<sub>Reg</sub>) cells suppress inflammatory responses and maintain intestinal homeostasis, and therefore they might mitigate the formation of inflammation-associated tumours. Surprisingly, Geis *et al.* have found that in mice colonized with enterotoxigenic *Bacteroides fragilis* (ETBF) — a human colonic bacterium associated with inflammatory intestinal diseases — T<sub>Reg</sub> cells produce interleukin-17, which promotes the earliest stages of colon carcinogenesis. Depletion of T<sub>Reg</sub> cells in ETBF-colonized mice enhanced colitis but diminished tumorigenesis.

**ORIGINAL RESEARCH PAPER** Geis, A. L. *et al.* Regulatory T cell response to enterotoxigenic *Bacteroides fragilis* colonization triggers IL-17-dependent colon carcinogenesis. *Cancer Discov.* <http://dx.doi.org/10.1158/2159-8290.CD-15-0447> (2015)

 GENETICS**The evil twin**

Some cancers have an abundance of mutations at cytosines on one DNA strand, which is consistent with the mutagenic properties of APOBEC cytidine deaminases. *APOBEC3B* mRNA expression has been found in various cancers, whereas the role of *APOBEC3A* as a mutator is less clear. By analysing 15 cohorts of recently published whole-genome sequencing samples that included 5 different types of cancer with mutation signatures resembling those of either APOBEC, Chan *et al.* have found that *APOBEC3A* is the predominant mutagenic deaminase. Although *APOBEC3B* mRNA tends to be more abundant than that of *APOBEC3A*, *APOBEC3A* is a much more potent inducer of mutations than *APOBEC3B*.

**ORIGINAL RESEARCH PAPER** Chan, K. *et al.* An *APOBEC3A* hypermutation signature is distinguishable from the signature of background mutagenesis by *APOBEC3B* in human cancers. *Nat. Genet.* <http://dx.doi.org/10.1038/ng.3378> (2015)

 THERAPY**Reinventing the wheel**

Huang *et al.* have identified that the potassium channel ether-a-go-go 2 (EAG2) promotes tumour growth and metastasis in multiple fly and mouse brain tumour models. In a xenograft model of medulloblastoma, EAG2 knockdown impaired metastasis, and pharmacological inhibition of EAG2 with an FDA-approved antipsychotic drug, thioridazine, showed potent efficacy in reducing intracranial tumour growth and metastasis.

**ORIGINAL RESEARCH PAPER** Huang, X. *et al.* EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. *Nat. Neurosci.* <http://dx.doi.org/10.1038/nn.4088> (2015)